After the withdrawal of rapamycin treatment, mutated COL1A1 reinforced PI3K–AKT-mammalian target of rapamycin (mTOR) signals in cancer stem cells to sustain the metastatic burden of ERα-positive breast cancer cells; however, lung metastases were independent of mTOR signaling [74]. Here, ESR1 is linked to breast carcinoma.